albumin - publications
Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
Expert Rev Pharmacoecon Outcomes Res. 2013 Mar 28;
Authors: Alba E, Ciruelos E, López R, López-Vega JM, Lluch A, Martín M, Muñoz M, Sánchez-Rovira P, Seguí MA, Liria MR, Pérez-Alcántara F
Aim: The COSTABRAX study evaluated the cost-effectiveness of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) versus polyethylated castor oil-based standard paclitaxel (sb-paclitaxel) in the treatment of patients with previously treated metastatic breast cancer in Spain. Materials & methods: Efficacy data were obtained from the CA012 trial (nab-paclitaxel administered every 3 weeks [q3w] and sb-paclitaxel q3w) and indirect comparison (sb-paclitaxel administered weekly), and were modeled to a time horizon of 5 years using a Markov model. The analysis was performed from the National Health Service perspective. Use of resources and key assumptions of the model were validated by a panel of 22 local oncologists. Results: Compared with sb-paclitaxel q3w, nab-paclitaxel q3w was cost effective, with a cost per life-year gained of €11,088 and a cost per quality-adjusted life-year of €17,808. Compared with sb-paclitaxel administered weekly, it showed savings of €711 per patient. Conclusion: The COSTABRAX study showed that nab-paclitaxel q3w is a cost-effective alternative compared with sb-paclitaxel q3w and a cost-saving alternative to sb-paclitaxel administered weekly in Spain.
PMID: 23534988 [PubMed - as supplied by publisher]